Publications

Steinlauf AF, Garcia-Tsao G, Zakko MF, Dickey K, Gupta T, Groszmann RJ.  1999.  Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements.. Hepatology. 29(4):1070-3.

Steinlauf AF, Garcia-Tsao G, Zakko MF, Dickey K, Gupta T, Groszmann RJ.  1999.  Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements.. Hepatology. 29(4):1070-3.

Steinlauf AF, Garcia-Tsao G, Zakko MF, Dickey K, Gupta T, Groszmann RJ.  1999.  Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements.. Hepatology. 29(4):1070-3.

Yang A, Chen Y, Scherl E, Neugut AI, Bhagat G, Green PHR.  2005.  Inflammatory bowel disease in patients with celiac disease.. Inflamm Bowel Dis. 11(6):528-32.

Otani T, Yamaguchi K, Scherl E, Du B, Tai H-H, Greifer M, Petrovic L, Daikoku T, Dey SK, Subbaramaiah K et al..  2006.  Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.. Am J Physiol Gastrointest Liver Physiol. 290(2):G361-8.

Harris A, Eswaran S, Bosworth B, Gambarin-Gelwan M, Scherl EJ.  2007.  Mesalamine-induced Pneumonitis and Serum Sickness-like Reaction.. Gastroenterol Hepatol (N Y). 3(11):875-7.

Longman RS, Remotti H, Green PH.  2011.  Esophagitis dissecans superficialis.. Gastrointest Endosc. 74(2):403-4.

Steinlauf AF, Marion JF, Sacchar D, Sandler AL, Greenstein AJ, Harris MT.  2011.  Ileouterine fistulae: possible predisposing factors to this rare complication of Crohn's disease.. Inflamm Bowel Dis. 17(3):872-3.

Shen T-CDavid, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D et al..  2012.  Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.. J Clin Neuromuscul Dis. 13(3):137-45.

Longman RS, Moreira RK, Littman DR, Green PHR, Sethi A.  2012.  A rare intestinal infection with systemic effects.. Gastroenterol Hepatol (N Y). 8(1):60-3.

Koczka CPhilip, Abramowitz M, Goodman AJ.  2012.  The study of bone demineralization and its risk factors in an Afro-Caribbean subset of patients with inflammatory bowel disease.. Eur J Gastroenterol Hepatol. 24(7):759-61.

Diehl GE, Longman RS, Zhang J-X, Breart B, Galan C, Cuesta A, Schwab SR, Littman DR.  2013.  Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells.. Nature. 494(7435):116-20.

Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..  2013.  Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.

Longman RS, Diehl GE, Victorio DA, Huh JR, Galan C, Miraldi ER, Swaminath A, Bonneau R, Scherl EJ, Littman DR.  2014.  CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.. J Exp Med. 211(8):1571-83.

Chen HJoyce, Sun J, Huang Z, Hou H, Arcilla M, Rakhilin N, Joe DJ, Choi J, Gadamsetty P, Milsom J et al..  2015.  Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.. Nat Biotechnol. 33(6):656-60.

Chen HJoyce, Sun J, Huang Z, Hou H, Arcilla M, Rakhilin N, Joe DJ, Choi J, Gadamsetty P, Milsom J et al..  2015.  Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.. Nat Biotechnol. 33(6):656-60.

Gerbarg PL, Jacob VE, Stevens L, Bosworth BP, Chabouni F, DeFilippis EM, Warren R, Trivellas M, Patel PV, Webb CD et al..  2015.  The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial.. Inflamm Bowel Dis. 21(12):2886-96.

Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V et al..  2017.  Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.. Inflamm Bowel Dis. 23(6):903-911.

Borges LF, Jagadeesan V, Goldberg H, Gavini S, Lo W-K, Burakoff R, Feldman N, Chan WW.  2018.  Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis.. J Neurogastroenterol Motil. 24(3):395-402.

Borges LF, Jagadeesan V, Goldberg H, Gavini S, Lo W-K, Burakoff R, Feldman N, Chan WW.  2018.  Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis.. J Neurogastroenterol Motil. 24(3):395-402.

Cohen-Mekelburg S, Rosenblatt R, Gold S, Burakoff R, Waljee AK, Saini S, Schackman BR, Scherl E, Crawford C.  2018.  The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients.. J Crohns Colitis. 12(9):1030-1035.

Castellanos JG, Woo V, Viladomiu M, Putzel G, Lima S, Diehl GE, Marderstein AR, Gandara J, Perez AR, Withers DR et al..  2018.  Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.. Immunity. 49(6):1077-1089.e5.

Ghosh G, Jacob V, Wan D.  2018.  Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy.. Clin Gastroenterol Hepatol. 16(4):e41-e42.

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..  2018.  Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.

Gold SL, Magro C, Scherl E.  2018.  A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn's Disease.. Gastroenterology. 155(4):981-982.